Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

BACKGROUND: Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) improved progression free (PFS) and overall survival (OS) versus TMZ alone. Previous data indicate a ≥ 75% daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Toms, S. A., Kim, C. Y., Nicholas, G., Ram, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342854/
https://www.ncbi.nlm.nih.gov/pubmed/30506499
http://dx.doi.org/10.1007/s11060-018-03057-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342854/
https://www.ncbi.nlm.nih.gov/pubmed/30506499
http://dx.doi.org/10.1007/s11060-018-03057-z

Ejemplares similares